Treatment Compliance in Children and Adolescents on ADHD Medication
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The primary research objective of this observational study is to evaluate treatment
compliance over one year in children and adolescents who are newly initiated on medication
approved for the treatment of ADHD in a routine clinical setting. Compliance will be assessed
using the Pediatric Compliance Self-Rating (PCSR) Instrument. A patient will be considered as
compliant at a given visit, if the PCSR score is at least 5, corresponding to taking the
medication at least often.
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Atomoxetine Hydrochloride Central Nervous System Stimulants